NMTR News and Press, 9 Meters Biopharma Inc. From 06/30/21

Why These Penny Stocks Could Be Worth Adding to Your Watchlist Finding the most trending penny stocks is something that has become commonplace in the past year. With the advent of social media investors, penny stocks on Reddit , Twitter, and more have become very popular in 2021. Ad...

8 Penny Stocks to Watch Right Now As we head into a new month, finding the best penny stocks to buy is a great tactic for profitability. However, like many things, this is much easier said than done. With penny stocks , the most important thing to consider is that they are highly sp...

9 Meters Biopharma ([[NMTR]] -5.4%) as 10% owner, OrbiMed Israel GP and OrbiMed Israel BioFund GP Limited Partnership sold ~17.15M shares at $1.21 - $1.38 for a total transaction value of ~$24.16M.This brings the owner's total share holding to 8,565,974.The stock has ...

RALEIGH, NC / ACCESSWIRE / June 28, 2021 / 9 Meters Biopharma, Inc. (NASDAQ:NMTR), a clinical-stage biotechnology company focused on rare and unmet needs in gastroenterology, announced today it has joined the broad-market Russell 3000 ® Index and the small-cap Russell 2000 ® Inde...

Nine Meters Biopharma (NMTR) is a biotechnology company focusing on patients with gastrointestinal issues for which no treatments currently exist, explains Adam Johnson, growth stock expert and editor of Bullseye Brief. For further details see: Top Picks Mid-Year Updates- Nine Meters Bi...

9 Meters Biopharma (NMTR) has initiated its Phase 2 trial of vurolenatide, a proprietary long-acting glucagon-like peptide-1 (GLP-1) agonist in adults with short bowel syndrome ((SBS)). The Phase 2 trial, known as the VIBRANT is expected to enroll approx. 22 patients. The trial protocol has a...

Initiating the largest Phase 2 placebo-controlled trial in short bowel syndrome Topline results of the multicenter VIBRANT study anticipated in Q4 2021 RALEIGH, NC / ACCESSWIRE / June 14, 2021 / 9 Meters Biopharma, Inc. (NASDAQ:NMTR), a clinical-stage biotechnology company focused ...

RALEIGH, NC / ACCESSWIRE / June 9, 2021 / 9 Meters Biopharma, Inc. (NASDAQ:NMTR), a clinical-stage company focused on rare and unmet needs in gastroenterology, today announced that John Temperato, CEO of 9 Meters Biopharma will deliver a company presentation at 2021 BIO Digital being held ...

Organon attracts neutral views on the first day of tradingMerck (MRK) spinoff focused on women’s health and biosimilars, Organon (OGN), staged a late-afternoon rally to end ~8.4% higher yesterday on its first day of trading as a separate entity.In contrast to two buy ratings it pr...

Senseonics Holdings SENS +34% on the study results for glucose monitoring system.Windtree Therapeutics (WINT) +28%.The9 Limited NCTY +18% on Montcrypto acquisition.SemiLEDs Corporation (LEDS) +16%.Q&K International Group Limited (QK) +15%.Core Laboratories N.V. (CLB) +...